ArticleCancer cell international2025
Very long-chain fatty acids accumulate in breast cancer tissue and serum.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer.International journal of molecular sciences · 2026Article
- Article
- The Cuproptosis-Associated AL139023.1/miR-139-5p/ELOVL5 ceRNA Axis Regulates Proliferation, Migration, and Cell Cycle in Esophageal Squamous Cell Carcinoma.Cancer management and research · 2026Article
- Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance.Frontiers in oncology · 2026Review
- Serum fatty acid profiles across clinicopathologic heterogeneity in breast cancer: an exploratory study.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBreast cancer (BC) remains one of the most common cancers with relatively high mortality and is associated with alterations in fatty acid (FA) metabolism. While typical FAs have been extensively studied, there is increasing evidence for a potential role of very long chain fatty acids (VLCFAs) in cancer growth and progression.
methodsThis study involved 54 BC patients from whom samples of malignant tumor, normal fibroglandular tissue, and breast adipose tissue were collected. Their FA content was analyzed by gas chromatography-mass spectrometry. The expression of fatty acid elongases (ELOVLs) and FA-transporting proteins was analyzed in the tissues by RT-PCR and immunofluorescence.
resultsHigher levels of saturated and monounsaturated VLCFAs were found in BC tissues compared to normal tissues (p < 0.001) and in patients' blood compared to healthy controls blood (p < 0.001). However, the level of VLCFAs was lower in BC adipose tissue compared to healthy control adipose tissue (p < 0.001). Interestingly, there were no obvious differences in ELOVL1 mRNA or protein levels between normal and cancer tissues.
conclusionsElevated levels of VLCFAs in BC tissue are the result of lipid uptake from outside the tumor rather than in situ synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.